文献速递瓣膜病与结构性心脏病

药物相关瓣膜性心脏病与5-羟色胺通路:一项荟萃分析

Drug-associated valvular heart diseases and serotonin-related pathways: a meta-analysis.
PubMed 文献 · Heart · 2019-05-25

该荟萃分析检索PubMed,纳入评估5-羟色胺能活性药物与心脏瓣膜病变关联的合格研究。结果显示5-羟色胺能药物(OR 3.30,95%CI 1.99-5.49)和多巴胺能药物(OR 2.56,95%CI 1.68-3.91)与瓣膜病存在一致显著关联。多数研究为回顾性或观察性,存在选择偏倚和呈现偏倚风险。

要点

  • 5-羟色胺能药物与瓣膜病显著相关(OR 3.30,95%CI 1.99-5.49)。
  • 多巴胺能药物与瓣膜病显著相关(OR 2.56,95%CI 1.68-3.91)。
  • 亚组分析限于单一药物或单一瓣膜时关联仍显著。

核心结论

  • 多种影响5-羟色胺通路的药物与瓣膜性心脏病存在一致显著关联。

研究设计与样本

  • 检索PubMed,排除病例报告、非对照研究和体外研究,对合格研究进行质量与偏倚评估后定量合成。

主要发现

  • 5-羟色胺能药物与瓣膜病关联OR 3.30(95%CI 1.99-5.49)。
  • 多巴胺能药物与瓣膜病关联OR 2.56(95%CI 1.68-3.91)。
  • 限于单一药物或单一瓣膜的亚组分析关联仍显著。
  • 研究间存在显著异质性,尤其暴露剂量和持续时间变异大。

临床怎么用

  • 对使用5-羟色胺能或多巴胺能药物的患者应关注瓣膜病风险。

局限性

  • 多数研究为回顾性或观察性,选择偏倚和呈现偏倚风险较高。
  • 研究间异质性显著,暴露剂量和持续时间变异大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Serotonergic appetite suppressants and ergot-derived dopamine agonists have been associated with drug-induced valvular heart disease. The purpose of this meta-analysis is to synthesise the current evidence of a link between several medications affecting sertonergic pathways and valvular heart disease. METHODS: PubMed was searched to identify studies evaluating an association between medications with serotonergic activity and cardiac valvular pathology. Case reports, uncontrolled studies and in vitro studies were excluded. Relevant studies were assessed for quality and potential bias; those of adequate quality were included in a quantitative synthesis. Sensitivity analyses were conducted, and potential publication bias was examined. RESULTS: There was a consistent, significant relationship between certain medications and heart valve disease, including serotonergic medications (OR 3.30, 95% CI 1.99 to 5.49) and dopaminergic medications (OR 2.56, 95% CI 1.68 to 3.91). Subanalyses, including analyses that limited exposure to a single medication or effects to a single heart valve were also consistently significant. Most studies were retrospective or observational in nature, with a higher risk of selection and presentation biases. There was significant heterogeneity and variability between studies, particularly when it came to dose and duration of exposure. CONCLUSIONS: There was a consistent, significant association between many medications that affect serotonergic pathways and valvular heart disease. Although many of these medications have been withdrawn from the market, some small studies suggest that recreational drug 3,4-methylenedioxymethamphetamine and widely prescribed selective serotonin reuptake inhibitors may affect similar pathways.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Fortier JH, Pizzarotti B, Shaw RE, et al. Drug-associated valvular heart diseases and serotonin-related pathways: a meta-analysis. Heart. 2019. PMID: 31129607. doi:10.1136/heartjnl-2018-314403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。